Daiwa Securities Group Inc. Takes $28,000 Position in Novo Nordisk A/S (NYSE:NVO)

Daiwa Securities Group Inc. purchased a new position in Novo Nordisk A/S (NYSE:NVO) during the third quarter, Holdings Channel.com reports. The firm purchased 232 shares of the company’s stock, valued at approximately $28,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. International Assets Investment Management LLC increased its position in shares of Novo Nordisk A/S by 10,608.4% in the third quarter. International Assets Investment Management LLC now owns 1,813,571 shares of the company’s stock worth $215,942,000 after acquiring an additional 1,796,635 shares in the last quarter. DSM Capital Partners LLC raised its stake in Novo Nordisk A/S by 257,816.0% during the 2nd quarter. DSM Capital Partners LLC now owns 1,593,921 shares of the company’s stock valued at $227,516,000 after purchasing an additional 1,593,303 shares during the period. Mediolanum International Funds Ltd purchased a new stake in shares of Novo Nordisk A/S in the third quarter valued at $98,765,000. Marshall Wace LLP boosted its position in shares of Novo Nordisk A/S by 34,472.1% in the second quarter. Marshall Wace LLP now owns 691,441 shares of the company’s stock worth $98,696,000 after buying an additional 689,441 shares during the period. Finally, Sanctuary Advisors LLC purchased a new position in shares of Novo Nordisk A/S during the second quarter valued at $41,646,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Performance

NVO stock opened at $106.80 on Monday. The firm has a 50 day moving average of $112.81 and a two-hundred day moving average of $127.92. Novo Nordisk A/S has a 12 month low of $94.73 and a 12 month high of $148.15. The company has a market capitalization of $479.27 billion, a price-to-earnings ratio of 34.56, a P/E/G ratio of 1.38 and a beta of 0.42. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.43.

Analyst Upgrades and Downgrades

NVO has been the subject of a number of research reports. StockNews.com upgraded Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research report on Friday, November 1st. BMO Capital Markets lowered their price objective on shares of Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating on the stock in a research report on Thursday, October 17th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Novo Nordisk A/S currently has a consensus rating of “Buy” and an average price target of $144.50.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.